On July 1, 2014, possession of cannabidiol extract was legalized for a narrow group of patients who suffer from intractable epilepsy and their caregivers through the state’s first Medical Cannabidiol Act.
On May 12, 2017, Governor Terry Brandstand signed House Bill 524, which legalized the use of low-THC cannabis oil for patients who suffer from one or more of eight (8) qualifying conditions, as well as terminal illness with a life expectancy of less than one year. Additionally, HB 524 provides for the establishment of the regulated cultivation and sale of marijuana for the purpose of producing low-TCH cannabis oil.
Certified physicians may only recommend medical marijuana for the following conditions:
Cancer (with severe or chronic pain, nausea or severe vomiting, cachexia or severe wasting)
Multiple sclerosis with severe and persistent muscle spasms
AIDS or HIV (as defined in Iowa Code, section 141A.1)
Amyotrophic lateral sclerosis (ALS)
Any terminal illness, with a probable life expectancy of under one year (if the illness or its treatment produces one or more of the following: severe or chronic pain, nausea or severe vomiting; cachexia or severe wasting)
The application periods for both types of licenses are now closed.
Applications for dispensaries were due on March 8, 2018 at 4 p.m.
Dispensaries must be licensed by April 1, 2018. The initial license effective period is April 1 – November 30, 2018.
A Notice of Intent to award licenses will be posted on March 26, 2018.
The Department of Public Health was required to license manufacturing facilities by December 1, 2017 and issued one (1) license to MedPharm Iowa. The Department reserves the right to re-issue a competitive bid for the second license. This may occur in late Spring 2018, after dispensary licenses are issued.
The program must be operational by December 1, 2018.
Application Fees/Start-up Costs
The application fee for a manufacturing facility is $7,500.
The application fee for a dispensary is $5,000.
The Department of Consumer Protection intends on licensing between three (3) and ten (10) new dispensaries. Holders of dispensary licenses may operate at up to five (5) locations.
Pistil + Stigma is a consulting firm working with organizations in public, private, and nonprofit sectors on groundbreaking policy issues nationwide. Customizable documents available from our subsidiary, Greenlight Drafts, empower you to bring your ideas to fruition and give your cannabis business a competitive advantage in your market.